Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 42, Issue 4, 2015, Pages 349-373

  Tsamandouras, Nikolaos ^a   Wendling, Thierry ^a   Rostami Hodjegan, Amin ^a,b   Galetin, Aleksandra ^a   Aarons, Leon ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CERTARA UK LIMITED   (United Kingdom)

Author keywords

Constraints; Logistic normal; Logit normal; PBPK; Population pharmacokinetics; Variability

Indexed keywords

DIAZEPAM;

ARTICLE; DATA ANALYSIS; HUMAN; METHODOLOGY; PHARMACOKINETICS; PHYSIOLOGY; POPULATION; PRIORITY JOURNAL; SIMULATION; STOCHASTIC MODEL; BIOLOGICAL MODEL; COMPUTER SIMULATION; HEALTH SURVEY; MARKOV CHAIN; NORMAL DISTRIBUTION;

COMPUTER SIMULATION; HUMANS; MODELS, BIOLOGICAL; NORMAL DISTRIBUTION; PHARMACOKINETICS; PHYSIOLOGY; POPULATION SURVEILLANCE; STOCHASTIC PROCESSES;

EID: 84938213461     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-015-9418-0     Document Type: Article

References (52)

1. Tsamandouras N, Rostami-Hodjegan A, Aarons L (2015) Combining the “bottom-up” and “top-down” approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data. Br J Clin Pharmacol 79(1):48–55
2. Tsamandouras N, Dickinson G, Guo Y, Hall S, Rostami-Hodjegan A, Galetin A, Aarons L (2015) Development and application of a mechanistic pharmacokinetic model for simvastatin and its active metabolite simvastatin acid using an integrated population PBPK approach. Pharm Res 32(6):1864–1883. doi:10.1007/s11095-014-1581-2
3. Aitchison J, Shen SM (1980) Logistic-normal distributions: some properties and uses. Biometrika 67(2):261–272
4. Lavielle M (2014) Mixed effects models for the population approach. Models, tasks, methods & tools. Chapman & Hall/CRC Biostatistics Series, Boca Raton
5. van der Walt JS, Hong Y, Zhang L, Pfister M, Boulton DW, Karlsson MO (2013) A nonlinear mixed effects pharmacokinetic model for dapagliflozin and dapagliflozin 3-o-glucuronide in renal or hepatic impairment. CPT: Pharmacomet Syst Pharmacol 2:e42
6. Gueorguieva I, Aarons L, Rowland M (2006) Diazepam pharamacokinetics from preclinical to Phase I using a Bayesian population physiologically based pharmacokinetic model with informative prior distributions in Winbugs. J Pharmacokinet Pharmacodyn 33(5):571–594
7. Langdon G, Gueorguieva I, Aarons L, Karlsson M (2007) Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM. Eur J Clin Pharmacol 63(5):485–498
8. Gelman A, Carlin JB, Stern HS, Rubin DB (1995) Bayesian data analysis, 1st edn. Chapman & Hall, London
9. Coleman T, Li Y (1996) An interior trust region approach for nonlinear minimization subject to bounds. SIAM J Optimiz 6(2):418–445
10. Aitchison J (1982) The statistical analysis of compositional data. J Roy Stat Soc B Met 44(2):139–177
11. Blei DM, Lafferty JD (2007) A correlated topic model of science. Ann Appl Stat 1(1):17–35
12. Minka T (2000) Estimating a Dirichlet distribution. Technical report. http://researchmicrosoftcom/en-us/um/people/minka/papers/dirichlet/minka-dirichletpdf
13. Read NW, Al-Janabi MN, Holgate AM, Barber DC, Edwards CA (1986) Simultaneous measurement of gastric emptying, small bowel residence and colonic filling of a solid meal by the use of the gamma camera. Gut 27(3):300–308
14. Read NW, Cammack J, Edwards C, Holgate AM, Cann PA, Brown C (1982) Is the transit time of a meal through the small intestine related to the rate at which it leaves the stomach? Gut 23(10):824–828
15. Zhang X, Lionberger RA, Davit BM, Yu LX (2011) Utility of physiologically based absorption modeling in implementing quality by design in drug development. AAPS J 13(1):59–71
16. Peters SA (2008) Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis. Clin Pharmacokinet 47(4):261–275
17. Lartigue S, Bizais Y, Bruley des Varannes S, Murat A, Pouliquen B, Galmiche JP (1994) Inter- and intrasubject variability of solid and liquid gastric emptying parameters. Dig Dis Sci 39(1):109–115
18. Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, Tucker G (2009) Population-based mechanistic prediction of oral drug absorption. AAPS J 11(2):225–237
19. Yu LX, Crison JR, Amidon GL (1996) Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int J Pharm 140(1):111–118
20. Gertz M, Tsamandouras N, Säll C, Houston JB, Galetin A (2014) Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk. Pharm Res 31(9):2367–2382
21. Kawai R, Mathew D, Tanaka C, Rowland M (1998) Physiologically based pharmacokinetics of Cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human. J Pharmacol Exp Ther 287(2):457–468
22. Price PS, Conolly RB, Chaisson CF, Gross EA, Young JS, Mathis ET, Tedder DR (2003) Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit Rev Toxicol 33(5):469–503
23. ® population-based ADME simulator. Expert Opin Drug Metab Toxicol 5(2):211–223
24. Wendling T, Ogungbenro K, Pigeolet E, Dumitras S, Woessner R, Aarons L (2014) Model-based evaluation of the impact of furmulation and food intake on the complex oral absorption of mavoglurant in healthy subjects. Pharm Res 32(5):1764–1778. doi:10.1007/s11095-014-1574-1
25. Zhou H (2003) Pharmacokinetic strategies in deciphering atypical drug absorption profiles. J Clin Pharmacol 43(3):211–227
26. Csajka C, Drover D, Verotta D (2005) The use of a sum of inverse Gaussian functions to describe the absorption profile of drugs exhibiting complex absorption. Pharm Res 22(8):1227–1235
27. Rowland M, Peck C, Tucker G (2011) Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 51(1):45–73
28. Nestorov I (2003) Whole body pharmacokinetic models. Clin Pharmacokinet 42(10):883–908
29. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13(4):407–484
30. Hoff PD (2003) Nonparametric modeling of hierarchically exchangeable data. University of Washington Statistics Department, Technical Report 421
31. Huang J, Malisiewicz T (2009) Fitting a hierarchical logistic normal distribution. Technical Report, Carnegie Mellon University
32. DiCiccio T, Efron B (1996) Bootstrap confidence intervals. Stat Sci 11(3):189–228
33. Klotz U, Antonin KH, Bieck PR (1976) Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. J Pharmacol Exp Ther 199(1):67–73
34. Greenblatt DJ, Allen MD, Harmatz JS, Shader RI (1980) Diazepam disposition determinants. Clin Pharmacol Ther 27(3):301–312
35. Rowland M, Leitch D, Fleming G, Smith B (1984) Protein binding and hepatic clearance: discrimination between models of hepatic clearance with diazepam, a drug of high intrinsic clearance, in the isolated perfused rat liver preparation. J Pharmacokinet Biopharm 12(2):129–147
36. Sorger PK, Allerheiligen SR, Abernethy DR, et al. (2011) Quantitative and systems pharmacology in the post-genomic era: New approaches to discovering drugs and understanding therapeutic mechanisms. An NIH white paper by the QSP workshop group: 1-48
37. Jusko WJ (2013) Moving from basic toward systems pharmacodynamic models. J Pharm Sci 102(9):2930–2940
38. Wulkersdorfer B, Wanek T, Bauer M, Zeitlinger M, Muller M, Langer O (2014) Using positron emission tomography to study transporter-mediated drug-drug interactions in tissues. Clin Pharmacol Ther 96(2):206–213
39. Plan EL, Elshoff JP, Stockis A, Sargentini-Maier ML, Karlsson MO (2012) Likert pain score modeling: a Markov integer model and an autoregressive continuous model. Clin Pharmacol Ther 91(5):820–828
40. Petersson KF, Hanze E, Savic R, Karlsson M (2009) Semiparametric distributions with estimated shape parameters. Pharm Res 26(9):2174–2185
41. Krewski D, Wang Y, Bartlett S, Krishnan K (1995) Uncertainty, variability, and sensitivity analysis in physiological pharmacokinetic models. J Biopharm Stat 5(3):245–271
42. Farrar D, Allen B, Crump K, Shipp A (1989) Evaluation of uncertainty in input parameters to pharmacokinetic models and the resulting uncertainty in output. Toxicol Lett 49(2–3):371–385
43. Gelman A, Bois F, Jiang J (1996) Physiological pharmacokinetic analysis using population modeling and informative prior distributions. J Am Stat Assoc 91(436):1400–1412
44. Bois FY (2000) Statistical analysis of Clewell et al. PBPK model of trichloroethylene kinetics. Environ Health Perspect 108(Suppl 2):307–316
45. Yang Y, Xu X, Georgopoulos PG (2010) A Bayesian population PBPK model for multiroute chloroform exposure. J Expo Sci Environ Epidemiol 20(4):326–341
46. Lindberg-Freijs A, Karlsson MO (1994) Dose dependent absorption and linear disposition of cyclosporin a in rat. Biopharm Drug Dispos 15(1):75–86
47. Silber HE, Frey N, Karlsson MO (2010) An integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteers. J Clin Pharmacol 50(3):246–256
48. Bizzotto R, Zamuner S, Mezzalana E, De Nicolao G, Gomeni R, Hooker AC, Karlsson MO (2011) Multinomial logistic functions in Markov chain models of sleep architecture: internal and external validation and covariate analysis. AAPS J 13(3):445–463
49. Gelman A (1995) Method of moments using Monte Carlo simulation. J Comput Graph Stat 4(1):36–54
50. Willmann S, Hohn K, Edginton A, Sevestre M, Solodenko J, Weiss W, Lippert J, Schmitt W (2007) Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 34(3):401–431
51. McNally K, Cotton R, Hogg A, Loizou G (2014) Popgen: a virtual human population generator. Toxicology 315:70–85
52. Krauß M, Tappe K, Burghaus R, Schuppert A, Kuepfer L, Goerlitz L (2014) Hierarchical Bayesian-PBPK modeling for physiological characterization and extrapolation of patient populations from clinical data. PAGE 23 (2014), Abstr 3151. www.page-meeting.org/?abstract=3151